/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
SASKATOON, SK, Feb. 9, 2026/CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce that it has filed an amended and restated offering document dated February 9, 2026 (the "Amended and Restated Offering Document") with respect to the offering (the "LIFE Offering") pursuant to and in accordance with the "listed issuer financing exemption" from the prospectus requirement available under section 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, previously announced on January 12, 2026, and offering of the units under the LIFE Offering has recommenced.
Read more at newswire.ca